Epidemiology of Hepatocellular Carcinoma

Lafaro, Kelly J.; Demirjian, Aram N.; Pawlik, Timothy M.

doi:10.1016/j.soc.2014.09.001

Cited by 267 publications

(219 citation statements)

References 90 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…В структуре пер-вичных злокачественных опухолей печени гепато-целлюлярный рак (ГЦР) составляет 85-90% [8]. К сожалению, в большинстве наблюдений ГЦР диа-гностируется в поздних стадиях, когда невозможно проведение радикального лечения.…”

Section: Introductionunclassified

Transarterial therapy for hepatocellular cancer

Chekunov

Polyakov

Bagment

et al. 2015

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

ВведениеПервичный рак печени занимает 5-е место по распространенности и 2-е по смертности среди он-кологических заболеваний, при этом в 2012 г. заре-гистрировано 782 000 заболевших. В структуре пер-вичных злокачественных опухолей печени гепато-целлюлярный рак (ГЦР) составляет 85-90% [8]. К сожалению, в большинстве наблюдений ГЦР диа-гностируется в поздних стадиях, когда невозможно проведение радикального лечения. Трансартериаль-ная химиоэмболизация (ТАХЭ) печени является ме-тодом выбора при промежуточной стадии ГЦР, ко-торая встречается наиболее часто. Селективность манипуляции позволяет минимизировать системное воздействие на организм и обеспечивает высокую эффективность за счет доставки химиоэмболизиру-ющих агентов непосредственно в сосудистое русло опухоли. Интерес вызывает также наличие широко-го разнообразия режимов выполнения ТАХЭ как в качестве монотерапии, так и в комбинации с други-ми терапевтическими опциями.Цель исследования -оценка результатов лече-ния больных ГЦР после ТАХЭ в качестве самостоя-тельной лечебной опции, «моста» к трансплантации печени и в рамках комбинированной терапии. Материал и методыВ исследовании ретроспективно проанализиро-ваны результаты лечения 29 больных ГЦР, которым Цель -оценить результаты лечения больных ГЦР после ТАХЭ в качестве самостоятельной лечебной опции, «моста» к трансплантации печени и в рамках комбинированной терапии. Материал и методы. Представлен опыт применения транс-артериальной химиоэмболизации (ТАХЭ) в лечении 29 больных гепатоцеллюлярным раком. Лечебные процедуры выпол-нены в рамках монотерапии, «моста» к трансплантации печени и комбинированного лечения. Суммарно было проведено 48 сеансов химиоэмболизации: один и два сеанса получили 44,9% больных, три процедуры -10,2% пациентов. Средний промежуток между сеансами равнялся 76,2±116,2 сут (8-139 сут). Результаты. Постэмболизационный синдром (повы-шение температуры тела, тошнота, боль) наблюдали у 24,1% больных после 1-го этапа, у 50 и 33,3% больных после 2-го и 3-го этапов соответственно. Средний период ожидания трансплантации печени в группе пациентов bridge therapy был равен 8,5±6,8 мес (1-20 мес). Медиана выживаемости после ТАХЭ в группе монотерапии составила 9 мес. Ключевые слова: гепатоцеллюлярный рак, трансартериальная терапия, химиоэмболизация.Aim. To estimate treatment of patients with hepatocellular cancer after transarterial chemoembolization as independent curative method, "bridge" to liver transplantation and in the context of combined therapy. Material and methods. We presented an experience of transarterial chemoembolization in treatment of 29 patients with hepatocellular cancer. Curative procedures were performed in the context of independent therapy, "bridge" to liver transplantation and combined treatment. It was performed 48 procedures in all. 44.9% of patients underwent one and two procedures, 10.2% -three performances. Mean interval between procedures was 76.2±116.2 days (range 8-139 days). Results. Post-embolization syndrome including fervescence, nausea and pain was observed in 24.1% aft...

show abstract

Section: Introductionunclassified

Transarterial therapy for hepatocellular cancer

Chekunov

Polyakov

Bagment

et al. 2015

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

show abstract

“…Apesar dos avanços na prevenção dos principais fatores de risco do HCC, a mortalidade associada a esta doença encontra-se ainda em aumento (LAFARO; DEMIRJIAN;PAWLIK, 2015;NORDENSTEDT;WHITE;EL-SERAG, 2010;TORRE et al, 2016). A resistência aos quimioterápicos e a alta taxa de reincidência tornam necessária a busca de novas estratégias terapêuticas.…”

Section: Discussionunclassified

“…Dentre os cânceres primários de fígado, o tipo mais frequente é o carcinoma hepatocelular (HCC) atingindo 85-90% das neoplasias de fígado diagnosticadas (LAFARO; DEMIRJIAN;PAWLIK, 2015). A incidência do HCC apresenta diferenças por gênero, sendo mais incidente em homens do que em mulheres (LAFARO; DEMIRJIAN;PAWLIK, 2015;TORRE et al, 2016), por regiões geográficas e índice de desenvolvimento humano (BRAY et al, 2012).…”

Section: Epidemiologia Do Câncer De Fígadounclassified

“…A incidência do HCC apresenta diferenças por gênero, sendo mais incidente em homens do que em mulheres (LAFARO; DEMIRJIAN;PAWLIK, 2015;TORRE et al, 2016), por regiões geográficas e índice de desenvolvimento humano (BRAY et al, 2012).…”

Section: Epidemiologia Do Câncer De Fígadounclassified

“…infecções crônicas pelos vírus das hepatites B (HBV) e C (HCV), consumo de bebidas alcoólicas, consumo de alimentos contaminados por aflatoxina e doença hepática gordurosa não alcoólica (NAFLD) (LAFARO; DEMIRJIAN;PAWLIK, 2015;TORRE et al, 2016). A alta prevalência de HBV na África e na Ásia…”

Section: Epidemiologia Do Câncer De Fígadounclassified

See 2 more Smart Citations

Caracterização do efeito anti-neoplásico do butirato em duas linhagens celulares de rato derivadas de tumores hepáticos com diferente nível de diferenciação

Méndez¹

View full text Add to dashboard Cite

The impact of different setup methods on the dose distribution in proton therapy for hepatocellular carcinoma

Takemasa

Katō

Narita

et al. 2021

J Applied Clin Med Phys

View full text Add to dashboard Cite

To investigate the impact of different setup methods, vertebral body matching (VM), diaphragm matching (DM), and marker matching (MM), on the dose distribution in proton therapy (PT) for hepatocellular carcinoma (HCC). Materials and Methods: Thirty-eight HCC lesions were studied retrospectively to assess changes in the dose distribution on two computed tomography (CT) scans. One was for treatment planning (1st-CT), and the other was for dose confirmation acquired during the course of PT (2nd-CT). The dose coverage of the clinical target volume (CTV-D 98) and normal liver volume that received 30 Gy relative biological effectiveness (RBE) (liver-V 30) were evaluated under each condition. Initial treatment planning on the 1st-CT was defined as reference, and three dose distributions recalculated using VM, DM, and MM on the 2nd-CT, were compared to it, respectively. In addition, the relationship between the CTV-D 98 of each method and the distance between the center of mass (COM) of the CTV and the right diaphragm top was evaluated. Results: For CTV-D 98 , significant differences were observed between the reference and VM and DM, respectively (P = 0.013, P = 0.015). There were also significant differences between MM and VM and DM, respectively (P = 0.018, P = 0.036). Regarding liver-V 30 , there was no significant difference in any of the methods, and there were no discernable difference due to the different setup methods. In DM, only two out of 34 cases with a distance from right diaphragm top to COM of CTV of 90 mm or less that CTV-D 98 difference was 5% or more and CTV-D 98 was worse than VM were confirmed. Conclusion: Although MM is obviously the most effective method, it is suggested that DM may be particularly effective in cases where the distance from right diaphragm top to COM of CTV of 90 mm or less.

show abstract

Epidemiology of Hepatocellular Carcinoma

Cited by 267 publications

References 90 publications

Transarterial therapy for hepatocellular cancer

Transarterial therapy for hepatocellular cancer

Caracterização do efeito anti-neoplásico do butirato em duas linhagens celulares de rato derivadas de tumores hepáticos com diferente nível de diferenciação

The impact of different setup methods on the dose distribution in proton therapy for hepatocellular carcinoma

Contact Info

Product

Resources

About

Epidemiology of Hepatocellular Carcinoma

Cited by 267 publications

References 90 publications

Transarterial therapy for hepatocellular cancer

Transarterial therapy for hepatocellular cancer

Caracterização do efeito anti-neoplásico do butirato em duas linhagens celulares de rato derivadas de tumores hepáticos com diferente ní­vel de diferenciação

The impact of different setup methods on the dose distribution in proton therapy for hepatocellular carcinoma

Contact Info

Product

Resources

About

Caracterização do efeito anti-neoplásico do butirato em duas linhagens celulares de rato derivadas de tumores hepáticos com diferente nível de diferenciação